Skyrizi

Product manufactured by Abbvie Inc.

Application Nr Approved Date Route Status External Links
BLA761105 None None None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Skyrizi ® Is Indicated For The Treatment Of Moderate-To-Severe Plaque Psoriasis In Adults Who Are Candidates For Systemic Therapy Or Phototherapy. Skyrizi Is An Interleukin-23 Antagonist Indicated For The Treatment Of Moderate-To-Severe Plaque Psoriasis In Adults Who Are Candidates For Systemic Therapy Or Phototherapy. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Risankizumab-Rzaa

Comments